Daratumumab Shows Promise in Smoldering Myeloma and Multiple Myeloma Trials
TL;DR Summary
Johnson & Johnson is seeking FDA and EMA approval for Darzalex (daratumumab) as a treatment for high-risk smoldering myeloma, based on positive results from the Phase 3 AQUILA trial. The study showed a 51% reduced risk of disease progression or death for patients treated with Darzalex compared to active monitoring. While some experts are optimistic about early treatment benefits, others caution that stronger therapies may be needed for patients likely to develop multiple myeloma.
Topics:business#clinical-trials#daratumumab#fda-approval#health#johnson-and-johnson#smoldering-myeloma
- Johnson & Johnson seeks first drug approval for treatment of smoldering myeloma STAT
- Daratumumab SC-based regimens show improved MRD negativity and PFS in Phase 3 NDMM trials World Pharmaceutical Frontiers
- Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma Pharmacy Times
- ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug BioPharma Dive
- Treatment of Smoldering Myeloma Cuts Progression Rate in Half Medpage Today
Reading Insights
Total Reads
0
Unique Readers
15
Time Saved
6 min
vs 7 min read
Condensed
94%
1,224 → 74 words
Want the full story? Read the original article
Read on STAT